Welcome to Prostate Answers, an online resource created to help you stay informed about advances in prostate cancer prevention, surveillance and treatment.
It is estimated that 1 in 6 men will develop prostate cancer in their lifetime, making this disease the most common cancer in men.
While early-stage prostate cancer is usually manageable with curative surgery or radiation therapy, some men will develop advanced prostate cancer that requires additional treatments
with hormone therapy or chemotherapy.
Explore the videos and articles on Prostate Answers, which all feature leaders in the field, to learn about treatment options for men with all types of prostate cancer.
  Ask Your Doctor
  Prostate Answers has provided you with a list of questions to Ask Your Doctor about Prostate Cancer
as well as tips for preparing for these conversations.
Early Stage Treatment
Late Stage Treatment
Ask Your Doctor
Resources

Chemotherapy Options for Prostate Cancer
Traditionally, chemotherapy had almost no role in treating prostate cancer. But today, new chemotherapy drugs have been proven to not only provide symptom relief, but also extend the lives of patients with advanced prostate cancer.

Prolonging Life in Prostate Cancer
As the second-most common cancer in the United States, prostate cancer will be diagnosed in over 230,000 men this year alone and almost 30,000 will die from the disease.
    Prostate Cancer Facts
prostate
  • Prostate cancer is the most common cancer in men

    • prostate
  • The American Cancer Society estimates that there will be about 218,890 new cases of prostate cancer in the United States in 2007.

    • prostate
  • Most cases of prostate cancer are diagnosed in an early stage

    • prostate
  • Based on cases diagnosed in 1995 and followed through 2000, 99% of all U.S. men diagnosed with prostate cancer will survive five years or longer
    		•
     
    prostate
    Register for
    Prostate
    Health Updates:
    Email:
    State: 
    Please send me general
    health updates
    		 
    This site has been produced in
    collaboration with the
    Prostate Cancer Foundation
    and supported through an
    educational grant from
    Sanofi-Aventis Oncology.